Citigroup's private equity arm Citigroup Venture Capital International, Baring Private Equity, TPG and 3i are the front-runners to acquire an equity stake in Sharekhan, the retail brokerage arm of the Mumbai-based SSKI group.
The increasing number of generic players tapping the US market for known molecules has resulted in pricing pressures and lean margins.
D Aravindakshan was the managing director of Kerala State Drugs and Pharmaceuticals at Alleppey for many years before taking over as the head of Agastya Biopharma
The Bombay Stock Exchange, Asia's oldest stock exchange, plans to launch a separate trading platform for small and medium enterprises. Sources close to the development said the BSE was preparing a strategy for an SME exchange.
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
Oman's largest bank BankMuscat, which recently picked up 43 per cent stake in the domestic brokerage house Mangal Keshav Group
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
The Securities and Exchange Board of India is expected to shortly release a circular asking mutual fund houses not to park more than 15 per cent of their corpus as bank deposits at any point of time.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Fortis Healthcare, promoted by the Singh family of Ranbaxy, plans to expand its network to 40 hospitals within three years by either acquiring new facilities or setting up greenfield projects
In its filing dated March 29, the company has said that its ability to develop the land reserves and generate the estimated developable area are subject to a number of risks such as defective title to the lands which could be legally challenged.
Beer is gaining more popularity in some of the non-traditional beer markets in North India like Rajasthan, Punjab, Delhi and Uttar Pradesh.
Amgen, the world's largest biotechnology company, has entered India by opening a wholly owned subsidiary Amgen Technology in Mumbai.
The much-awaited trading in corporate bonds will start on the National and the Bombay Stock Exchanges from July 1. This is expected to energise the moribund debt market.
Public sector undertakings Bharat Earth Movers (BEML), Rural Electrification Corporation (REC), Power Grid Corporation of India and National Hydroelectric Power Corporation (NHPC), are slated to hit the market with their IPOs.
EMI card is a unique installment concept, wherein you have the option of paying a fixed amount every month subject to the purchase limit you enjoy.
Unlike last year when private equity participants exited through strategic deals with third party investors, this year PEs are opting to exit via initial public offerings route.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances